NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Caplight Logo









Pulmonx

Pulmonx

Public
Redwood City, CaliforniaHealthcarewww.pulmonx.com

Last Round

Debt

Feb 1, 2023

Total Funding Raised

$555.2M

Company Overview

Pulmonx (NAS: LUNG) is a medical technology company that offers minimally invasive treatments for severe emphysema, including the Zephyr Endobronchial Valve and associated assessment systems.

Sector

Healthcare

AI Layer

Application

Keywords

endobronchial valve for severe emphysemaminimally invasive emphysema treatmentbronchoscopic lung volume reductionlung hyperinflation reduction devicecollateral ventilation assessment systemnon-surgical alternative to lung surgerycloud-based CT analysis for patient selectionsevere COPD treatment devicesingle-use pulmonology medical devicemedical device for interventional pulmonologyquantitative lung imaging analysis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pulmonx Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pulmonx Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
DebtFeb 1, 2023
IPO AnnouncedOct 5, 2020
Convertible DebtMay 5, 2020
Series GMay 9, 2019
Series F ExtensionJan 1, 2017
Series F
May 1, 2016

Pulmonx Investors

Notable investors and investment history

InvestorRounds
Canaccord GenuityIPO
Ally Bridge GroupSeries G, Convertible Debt
MedVenture AssociatesSeries A, Series D, Series C, Series B, Series E
BofA SecuritiesIPO
CIBC Innovation BankingDebt, Convertible Debt
HealthCapSeries D, Series E, Series C
Counterpoint Global (Morgan Stanley)IPO

Pulmonx Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pulmonx Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersRedwood City, California
Employee Range285
Year Founded1998
Last FundingFeb 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.